Application of Botulinum Toxin in Oral and Maxillofacial Surgery

Year 2013, Volume: 7 Issue: 2, 1469 - 1478, 01.07.2013

Kübra Titirinli İsmail Doruk Koçyiğit M Ercüment Önder Fethi Atıl Umut Tekin

Abstract

Injection of botulinum toxin, leads to temporary muscle paralysis by blocking the release of acetylcholine from the presynaptic neuron in neuromuscular junction. This is a dose-dependent reversible cosmetic and functional application. Botulinum toxin was used in the treatment of strabismus in 1980s for the first time. Application of botulinum toxin in dentistry has increased because of its minimal invasive nature with short operation time. In this article, the historical development of botulinum toxin, the structure and mechanism of action, market forms, dilution and storage conditions, toxicity, indications and contraindications, the possible development of resistance, uses in dentistry and oral maxillofacial surgery, and side effects are described with extensive literature review

Keywords

Botulinum toxins, dentistry, injections, toxicity

Oral ve Maksillofasiyal Cerrahide Botulinum Toksin Uygulamaları

Abstract

Botulinum toksin enjeksiyonu, nöromüsküler kavşakta presinaptik nöronlardan asetilkolin salınımını bloke ederek geçici kas paralizisine yol açan, etkisi doza bağımlı ve geri dönüşümlü kozmetik ve fonksiyonel bir uygulamadır. Botulinum toksin ilk kez 1980’li yıllarda strabismus tedavisinde kullanılmıştır. Minimal invaziv bir işlem oluşu ve operasyon süresinin kısa olması nedeniyle dişhekimliği alanında da botulinum toksin uygulamalarının kullanılabilirliği artmıştır. Bu derlemede, botulinum toksininin tarihsel gelişimi, yapısı ve etki mekanizması, ticari formları, dilüsyon ve saklama koşulları, toksisitesi, endikasyon ve kontrendikasyonları, olası direnç gelişimi, dişhekimliği ve oral maksillofasiyal cerrahide kullanım alanları ve olası yan etkileri geniş literatür desteği altında anlatılmıştır

Keywords

Botulinum toksini, diş hekimliği, enjeksiyonlar, toksisite

References

• Van Ermengem E. Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. Rev Infect Dis. 1979;1:701-19.
• Kwon JS, Kim ST, Jeon YM, Choi JH. Effect of botulinum toxin type A injection into human masseter muscle on stimulated parotid saliva flow rate. Int J Oral Maxillofac Surg. 2009;38:316- 20.
• Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol. 1949;109:10-24.
• Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc. 1981;79:734-70.
• Clark RP, Berris CE. Botulinum toxin: A treatment for facial asymmetry caused by facial nerve paralysis. Plast Reconstr Surg. 1989;84:353-5.
• Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18:17- 21.
• Chen S. Clinical uses of botulinum neurotoxins: Current indications, limitations and future developments. Toxins (Basel). 2012;4:913-39.
• Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 1981;33:155-88.
• Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther. 1980;212:16-21.
• Hambleton P. Clostridium botulinum toxins: A general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol. 1992;239:16-20.
• Dertzbaugh MT, West MW. Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum. Vaccine. 1996;14:1538-44.
• Trindade de Almeida AR, Marques E, de Almeida J, Cunha T, Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg. 2007;33(1 Spec No.):337-43.
• Carruthers J, Carruthers A. The evolution of botulinum neurotoxin type A for cosmetic applications. J Cosmet Laser Ther. 2007;9:186- 92.
• Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: Type B compared with type A. Neurology. 1997;49:189-94.
• Pary A, Pary K. Masseteric hypertrophy: Considerations regarding treatment planning decisions and introduction of a novel surgical technique. J Oral Maxillofac Surg. 2011;69:944- 9.
• Bonventre PF, Kempe LL. Physiology of toxin production by Clostridium botulinum types A and B. III. Effect of pH and temperature during incubation on growth, autolysis and toxin production. Appl Microbiol. 1959;7:374-7.
• Klein AW. Dilution and storage of botulinum toxin. Dermatol Surg. 1998;24:1179-80.
• Garcia A, Fulton JE Jr. Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose-response study. Dermatol Surg. 1996;22:39-43.
• Elmas C, Ayhan S, Tuncer S, Erdogan D, Calguner E, Basterzi Y, Gozil R, Bahçelioğlu M. Effect of fresh and stored botulinum toxin a on muscle and nerve ultrastructure: An electron microscopic study. Ann Plast Surg. 2007;59:316-22.
• Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol. 2000;43:249-59.
• Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53:407-15.
• Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45:1743-6.
• Pena MA, Alam M, Yoo SS. Complications with the use of botulinum toxin type A for cosmetic applications and hyperhidrosis. Semin Cutan Med Surg. 2007;26:29-33.
• Journal of Clinical Sciences